Published in Int J Stroke on June 02, 2014
Intravenous thrombolysis in acute ischemic stroke after dabigatran reversal with idarucizumab - a case report. Ann Clin Transl Neurol (2016) 0.88
Study of the Efficacy, Safety and Tolerability of Low-Molecular-Weight Heparin vs. Unfractionated Heparin as Bridging Therapy in Patients with Embolic Stroke due to Atrial Fibrillation. J Vasc Interv Neurol (2016) 0.80
Dabigatran-Associated Intracranial Hemorrhage: Literature Review and Institutional Experience. Neurohospitalist (2015) 0.75
Implications of apixaban for dental treatments. J Clin Exp Dent (2016) 0.75
Use of rivaroxaban in patients with stroke. Neurol Sci (2017) 0.75
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA (2001) 16.98
Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med (2013) 14.78
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med (2012) 11.86
A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest (2010) 10.29
A trial of imaging selection and endovascular treatment for ischemic stroke. N Engl J Med (2013) 9.97
Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med (2010) 9.92
Solitaire flow restoration device versus the Merci Retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial. Lancet (2012) 8.76
Endovascular treatment for acute ischemic stroke. N Engl J Med (2013) 8.45
Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial. Lancet (2012) 7.89
European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace (2013) 5.16
Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost (2010) 4.45
Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis. Stroke (2003) 3.12
A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med (2013) 2.84
A specific antidote for dabigatran: functional and structural characterization. Blood (2013) 2.77
Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials. Stroke (2007) 2.60
Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost (2010) 2.47
Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation (2012) 2.16
Laboratory assessment of new anticoagulants. Clin Chem Lab Med (2011) 1.99
Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol (2012) 1.85
Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion. Mayo Clin Proc (2007) 1.66
Enhanced detection of intracardiac sources of cerebral emboli by transesophageal echocardiography. Stroke (1991) 1.65
Early hemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome: results of a prospective multicenter study. Stroke (2008) 1.63
Anticoagulants for acute ischaemic stroke. Cochrane Database Syst Rev (2008) 1.49
Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost (2011) 1.47
Intravenous alteplase for stroke: beyond the guidelines and in particular clinical situations. Stroke (2007) 1.44
Use of the CHA(2)DS(2)-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation. Circulation (2012) 1.34
Hematoma expansion following acute intracerebral hemorrhage. Cerebrovasc Dis (2013) 1.30
Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. J Thromb Haemost (2013) 1.25
Poor prognosis in warfarin-associated intracranial hemorrhage despite anticoagulation reversal. Stroke (2012) 1.25
Optimal timing of resumption of warfarin after intracranial hemorrhage. Stroke (2010) 1.19
Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. Clin Res Cardiol (2013) 1.17
Frequency and risk factors for spontaneous hemorrhagic transformation of cerebral infarction. J Stroke Cerebrovasc Dis (2007) 1.06
Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet (2014) 1.05
Treatment of acute ischaemic stroke with thrombolysis or thrombectomy in patients receiving anti-thrombotic treatment. Lancet Neurol (2013) 1.04
Safety of intravenous thrombolysis for ischemic stroke in patients treated with warfarin. Ann Neurol (2013) 1.00
Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial. Clin Appl Thromb Hemost (2012) 0.99
Restarting anticoagulation therapy after warfarin-associated intracerebral hemorrhage. Arch Neurol (2008) 0.98
CHADS₂, CHA₂S₂DS₂-VASc, and long-term stroke outcome in patients without atrial fibrillation. Neurology (2013) 0.98
Determination of rivaroxaban in human plasma samples. Semin Thromb Hemost (2012) 0.97
Long-term management of patients after venous thromboembolism. Circulation (2004) 0.95
Monitoring of anticoagulant effects of direct thrombin inhibitors. Semin Thromb Hemost (2002) 0.94
Emergency reversal of anticoagulation: the real use of prothrombin complex concentrates: a prospective multicenter two year French study from 2006 to 2008. Thromb Res (2012) 0.93
Determination of dabigatran in human plasma samples. Semin Thromb Hemost (2012) 0.93
Predictors for recurrent primary intracerebral hemorrhage: a retrospective population-based study. Stroke (2013) 0.85
Symptomatic hemorrhagic transformation and its predictors in acute ischemic stroke with atrial fibrillation. Eur Neurol (2010) 0.83
Dabigatran etexilate: management in acute ischemic stroke. Am J Crit Care (2013) 0.83
Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban. J Thromb Haemost (2012) 0.82
Anticoagulant therapy for patients with ischaemic stroke. Nat Rev Neurol (2012) 0.82
Effects of blood pressure lowering on intracranial and extracranial bleeding in patients on antithrombotic therapy: the PROGRESS trial. Stroke (2012) 0.81
Should oral anticoagulants be restarted after warfarin-associated cerebral haemorrhage in patients with atrial fibrillation? Thromb Haemost (2013) 0.80
Implementing the new oral anticoagulants into the hospital formulary. Am J Hematol (2012) 0.77
Thrombolytic therapy for ischaemic stroke in patients using warfarin: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry (2012) 0.76
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25
Priority actions for the non-communicable disease crisis. Lancet (2011) 15.18
Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet (2010) 12.21
Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet (2010) 11.00
Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet (2007) 10.74
Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med (2015) 9.58
Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med (2005) 9.58
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol (2013) 6.18
Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials. Lancet Neurol (2007) 6.15
Idarucizumab for Dabigatran Reversal. N Engl J Med (2015) 5.91
Hemicraniectomy in older patients with extensive middle-cerebral-artery stroke. N Engl J Med (2014) 5.79
Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med (2008) 5.77
European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace (2013) 5.16
Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet (2008) 4.14
Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE collaboration): a meta-analysis of genome-wide association studies. Lancet Neurol (2012) 3.93
Results of the Stent-Protected Angioplasty versus Carotid Endarterectomy (SPACE) study to treat symptomatic stenoses at 2 years: a multinational, prospective, randomised trial. Lancet Neurol (2008) 3.91
Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke. Nat Genet (2012) 3.40
Predicting long-term outcome after acute ischemic stroke: a simple index works in patients from controlled clinical trials. Stroke (2008) 3.21
Stroke magnetic resonance imaging is accurate in hyperacute intracerebral hemorrhage: a multicenter study on the validity of stroke imaging. Stroke (2004) 3.07
Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke (2006) 3.03
Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol (2012) 2.77
Continuous stroke unit electrocardiographic monitoring versus 24-hour Holter electrocardiography for detection of paroxysmal atrial fibrillation after stroke. Stroke (2012) 2.64
Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurol (2009) 2.64
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol (2007) 2.56
Decompressive Surgery for the Treatment of Malignant Infarction of the Middle Cerebral Artery (DESTINY): a randomized, controlled trial. Stroke (2007) 2.56
EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J (2013) 2.52
Recommendations on angiographic revascularization grading standards for acute ischemic stroke: a consensus statement. Stroke (2013) 2.50
The stroke-thrombolytic predictive instrument: a predictive instrument for intravenous thrombolysis in acute ischemic stroke. Stroke (2006) 2.43
Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke. Stroke (2003) 2.42
MRI versus CT-based thrombolysis treatment within and beyond the 3 h time window after stroke onset: a cohort study. Lancet Neurol (2006) 2.42
Granulocyte colony-stimulating factor in patients with acute ischemic stroke: results of the AX200 for Ischemic Stroke trial. Stroke (2013) 2.36
Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace (2015) 2.35
Comparison of CT and CT angiography source images with diffusion-weighted imaging in patients with acute stroke within 6 hours after onset. Stroke (2002) 2.33
An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur Heart J (2007) 2.31
Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke (2004) 2.24
The Stroke Riskometer(TM) App: validation of a data collection tool and stroke risk predictor. Int J Stroke (2014) 2.18
Endovascular stroke therapy: tirofiban is associated with risk of fatal intracerebral hemorrhage and poor outcome. Stroke (2013) 2.11
Surgical decompression of patients with large middle cerebral artery infarcts is effective. Stroke (2003) 1.98
World Stroke Organization global stroke services guidelines and action plan. Int J Stroke (2014) 1.94
Recommendations for the management of intracranial haemorrhage - part I: spontaneous intracerebral haemorrhage. The European Stroke Initiative Writing Committee and the Writing Committee for the EUSI Executive Committee. Cerebrovasc Dis (2006) 1.91
Imaging-based decision making in thrombolytic therapy for ischemic stroke: present status. Stroke (2003) 1.90
Stroke MRI in intracerebral hemorrhage: is there a perihemorrhagic penumbra? Stroke (2003) 1.90
Determinants of intracerebral hemorrhage growth: an exploratory analysis. Stroke (2007) 1.90
Meta-analysis in more than 17,900 cases of ischemic stroke reveals a novel association at 12q24.12. Neurology (2014) 1.85
Sex differences in management and outcome after stroke: a Swedish national perspective. Stroke (2003) 1.78
Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor. Thromb Haemost (2012) 1.77
Smoking, clopidogrel, and mortality in patients with established cardiovascular disease. Circulation (2009) 1.77
Self-reported depression and use of antidepressants after stroke: a national survey. Stroke (2004) 1.70
Sex differences in stroke care and outcome in the Swedish national quality register for stroke care. Stroke (2008) 1.70
Point-of-care international normalized ratio testing accelerates thrombolysis in patients with acute ischemic stroke using oral anticoagulants. Stroke (2009) 1.69
Herpes simplex virus encephalitis despite normal cell count in the cerebrospinal fluid. Crit Care Med (2012) 1.67
Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion. Mayo Clin Proc (2007) 1.66
Acute stroke imaging research roadmap. Stroke (2008) 1.66
The main components of stroke unit care: results of a European expert survey. Cerebrovasc Dis (2007) 1.64
Baroreflex: a new therapeutic target in human stroke? Stroke (2009) 1.62
Shift analysis versus dichotomization of the modified Rankin scale outcome scores in the NINDS and ECASS-II trials. Stroke (2007) 1.62
Effectiveness and safety of transcranial laser therapy for acute ischemic stroke. Stroke (2009) 1.61
Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage. Stroke (2004) 1.60
Intra-arterial thrombolysis is the treatment of choice for basilar thrombosis: pro. Stroke (2006) 1.55
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. Eur Heart J (2013) 1.53
Leukocyte count as an independent predictor of recurrent ischemic events. Stroke (2004) 1.50
Comparison of the European and Japanese guidelines for the management of ischemic stroke. Cerebrovasc Dis (2013) 1.47
Acute Stroke Imaging Research Roadmap II. Stroke (2013) 1.47
Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J (2011) 1.47
APOE genotype and extent of bleeding and outcome in lobar intracerebral haemorrhage: a genetic association study. Lancet Neurol (2011) 1.47
Autonomic shift and increased susceptibility to infections after acute intracerebral hemorrhage. Stroke (2011) 1.46
Stenting for carotid artery stenosis. Nat Clin Pract Neurol (2007) 1.44
Functional outcome 3 months after stroke predicts long-term survival. Cerebrovasc Dis (2008) 1.43
Contemporary outcome measures in acute stroke research: choice of primary outcome measure. Stroke (2012) 1.43
Prevalence of stenoses and occlusions of brain-supplying arteries in young stroke patients. Neurology (2013) 1.42
Mismatch-based delayed thrombolysis: a meta-analysis. Stroke (2009) 1.41
Acute stroke imaging research roadmap. AJNR Am J Neuroradiol (2008) 1.41
Comparison of ABC/2 estimation technique to computer-assisted planimetric analysis in warfarin-related intracerebral parenchymal hemorrhage. Stroke (2005) 1.41
The Riks-Stroke story: building a sustainable national register for quality assessment of stroke care. Int J Stroke (2010) 1.40
Validation of Diagnoses of Transient Ischemic Attack in the Swedish Stroke Register (Riksstroke) TIA-Module. Neuroepidemiology (2015) 1.39
Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost (2015) 1.36
Shoulder pain after stroke: a prospective population-based study. Stroke (2006) 1.35
The Virtual International Stroke Trials Archive. Stroke (2007) 1.34
Magnetic resonance imaging evidence of cytotoxic cerebral edema in acute mountain sickness. J Cereb Blood Flow Metab (2006) 1.34
Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol (2002) 1.30
Determinants of quality of life in stroke survivors and their informal caregivers. Stroke (2005) 1.30
Stroke incidence and survival in the beginning of the 21st century in southern Sweden: comparisons with the late 20th century and projections into the future. Stroke (2007) 1.29
Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. J Am Heart Assoc (2013) 1.26